Published : 03/07/2019 - Categories : News
A new and unique revelation has been uncovered by Alsachim. For the first time ever, the one of a kind stable labeled standard of Thiotepa, [13C6] Thiotepa, is available. This represents a big step in the anticancer research field unlocking new information and discoveries.
Alsachim’s expertise in 13C labelling
In its desire to contribute to the fight against cancer, Alsachim has developed a unique labeled standard of Thiotepa [13C6] Thiotepa, a useful tool for you to advance in your research, in order to offer a more detailed analysis of this anticancer agent.
Alsachim has always been ahead of the game by developing a unique and complete products portfolio. Developing a “Gold Standard” labeling is the signature of Alsachim expertise and excellence.
Thiotepa, the anticancer drug
Since the mid-50’s, Thiotepa has been in the center of attention for anticancer research. It has been used as an alkylating agent with anticancer activity and has been studied and administrated for the treatment of solid cancers such as breast, ovary and bladder cancer.
More recently the Food and Drug Administration (FDA) has designated Thiotepa as a conditioning treatment for use prior to hematopoietic stem cell transplantation.
Thiotepa is currently being studied in the treatment of other types of cancer and as part of a regiment to prepare patients for bone marrow and stem cell transplantation.
Contact us now to get more information and a personalized quote.
Share this news
Search on news
- 2023 (4)
- 2022 (4)
- 2021 (4)
- 2020 (11)
- 2019 (4)
- 2018 (1)
- 2017 (1)